Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
The new ECO grade is made using renewable feedstock
This cell will serve as an extension of the Tele Mental Health Assistance and Networking Across States initiative of the Ministry of Health and Family welfare
Subscribe To Our Newsletter & Stay Updated
